<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);
    }
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 17.2 - Graves Disease</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 17.2 - Graves Disease | MD3 SCP Cases">
  <meta name="description" content="Medical case study for MD3 students.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:title" content="Case 17.2 - Graves Disease">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Medical case study for MD3 students.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 17.2 – Hyperthyroidism (Graves Disease)</h1>
    <p class="meta"><strong>Category:</strong> Endocrine & Reproductive Systems | <strong>Discipline:</strong> Medicine - Endocrinology | <strong>Setting:</strong> General Practice</p>

    <h2>Case</h2>
    <p>Shelley Hunter, a 35-year-old female presents with a recent history of feeling very agitated and nervous all the time. She has noticed that on occasions her heart is racing and she doesn't seem to 'feel the cold' as much as she used to.</p>
    <p>You observe that she appears to have a 'startled look', when you mention this she comments that her friends have mentioned something about her eyes as well.</p>

    <h2>Questions</h2>

    <div class="question">
      <strong>1. You are concerned that Shelley may have a problem with her thyroid, what are the key features of the history that you would explore with Shelley that would support a diagnosis of hyperthyroidism?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><em>Italics = common symptoms</em></p>
        
        <p><strong>General:</strong></p>
        <ul>
          <li><em>Weight loss despite normal or increased appetite</em></li>
          <li><em>Heat intolerance</em></li>
          <li><em>Fatigue, apathy</em></li>
          <li>Osteoporosis (fracture, loss of height)</li>
        </ul>

        <p><strong>Gastrointestinal:</strong></p>
        <ul>
          <li>Diarrhoea, steatorrhoea, hyperdefecation</li>
          <li>Anorexia</li>
          <li>Vomiting</li>
        </ul>

        <p><strong>Cardiovascular:</strong></p>
        <ul>
          <li><em>Palpitations</em></li>
          <li>Dyspnoea on exertion</li>
          <li>Angina</li>
          <li>Ankle swelling</li>
          <li>Exacerbation of asthma</li>
        </ul>

        <p><strong>Neuromuscular:</strong></p>
        <ul>
          <li>Anxiety, irritability, emotional lability, psychosis</li>
          <li>Tremor</li>
          <li>Muscle weakness</li>
          <li>Periodic paralysis (predominantly in Chinese)</li>
        </ul>

        <p><strong>Dermatological:</strong></p>
        <ul>
          <li><em>Sweating</em></li>
          <li>Pruritis</li>
          <li>Alopecia</li>
        </ul>

        <p><strong>Reproductive:</strong></p>
        <ul>
          <li>Amenorrhoea/oligomenorrhoea</li>
          <li>Infertility</li>
          <li>Spontaneous abortion</li>
          <li>Loss of libido, impotence</li>
        </ul>

        <p><strong>Ocular:</strong></p>
        <ul>
          <li>Grittiness, red eyes</li>
          <li>Excessive lacrimation</li>
          <li>Diplopia</li>
          <li>Loss of acuity</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>2. What are the key features on examination that support a diagnosis of hyperthyroidism? What are the clinical features specific to Graves's disease?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><em>Italics = most common, <strong>Bold = Graves specific</strong></em></p>

        <p><strong>General:</strong></p>
        <ul>
          <li><em>Weight loss</em></li>
          <li><strong>Goitre with bruit</strong></li>
        </ul>

        <p><strong>Cardiovascular:</strong></p>
        <ul>
          <li>Sinus tachycardia</li>
          <li>Atrial fibrillation</li>
          <li>Systolic hypertension/increased pulse pressure</li>
          <li>Cardiac failure</li>
        </ul>

        <p><strong>Haematological:</strong></p>
        <ul>
          <li>Lymphadenopathy (rare)</li>
        </ul>

        <p><strong>Neuromuscular:</strong></p>
        <ul>
          <li><em>Tremor</em></li>
          <li>Hyper-reflexia</li>
          <li>Ill-sustained clonus</li>
          <li>Proximal myopathy</li>
          <li>Bulbar myopathy (particularly in the elderly)</li>
        </ul>

        <p><strong>Dermatological:</strong></p>
        <ul>
          <li>Palmar erythema</li>
          <li><strong>Pretibial myxoedema</strong></li>
          <li><strong>Finger clubbing (thyroid acropachy)</strong></li>
          <li>Spider naevi (rare)</li>
          <li>Onycholysis (rare)</li>
          <li>Pigmentation (rare)</li>
          <li><strong>Vitiligo</strong></li>
        </ul>

        <p><strong>Reproductive:</strong></p>
        <ul>
          <li>Gynaecomastia</li>
        </ul>

        <p><strong>Ocular (Graves specific):</strong></p>
        <ul>
          <li><strong>Lid retraction, lid lag</strong></li>
          <li><strong>Chemosis</strong></li>
          <li><strong>Exophthalmos</strong></li>
          <li><strong>Periorbital oedema</strong></li>
          <li><strong>Corneal ulceration</strong></li>
          <li><strong>Ophthalmoplegia</strong></li>
          <li><strong>Papilloedema</strong></li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>3. What results on thyroid function testing would support a diagnosis of hyperthyroidism?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <table>
          <tr>
            <th>TSH</th>
            <th>T<sub>4</sub></th>
            <th>T<sub>3</sub></th>
            <th>Most likely interpretation(s)</th>
          </tr>
          <tr>
            <td>Undetectable</td>
            <td>Raised</td>
            <td>Raised</td>
            <td><strong>Primary thyrotoxicosis</strong></td>
          </tr>
          <tr>
            <td>Undetectable</td>
            <td>Normal</td>
            <td>Raised</td>
            <td><strong>Primary T<sub>3</sub>-toxicosis</strong></td>
          </tr>
          <tr>
            <td>Undetectable</td>
            <td>Normal</td>
            <td>Normal</td>
            <td><strong>Subclinical thyrotoxicosis</strong></td>
          </tr>
          <tr>
            <td>Undetectable</td>
            <td>Raised</td>
            <td>Low, normal or raised</td>
            <td>Sick euthyroidism/non-thyroidal illness</td>
          </tr>
          <tr>
            <td>Undetectable</td>
            <td>Low</td>
            <td>Low</td>
            <td>Secondary hypothyroidism (pituitary/hypothalamic disease) or transient thyroiditis in evolution</td>
          </tr>
          <tr>
            <td>Elevated</td>
            <td>High</td>
            <td>High</td>
            <td>Non-compliance with T<sub>4</sub> replacement-recent 'loading' dose; Secondary thyrotoxicosis-TSH-secreting pituitary tumour; Thyroid hormone resistance</td>
          </tr>
        </table>
      </div>
    </div>

    <div class="question">
      <strong>4. You explain to Shelley that she most likely has Graves Disease – What is the underlying pathophysiology of Grave's disease? Briefly outline other causes of hyperthyroidism.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Pathophysiology of Graves' Disease:</strong></p>
        <ul>
          <li>Graves thyrotoxicosis results from the production of IgG antibodies directed against the TSH receptor on the thyroid follicular cell</li>
          <li>These antibodies stimulate thyroid hormone production and, in the majority, goitre formation</li>
          <li>These antibodies are termed thyroid-stimulating immunoglobulins or TSH receptor antibodies (TRAb)</li>
          <li>Can be detected in the serum of 80-95% of patients with Graves' disease</li>
          <li>The concentration of TRAb in the serum is presumed to fluctuate to account for the natural history of Graves' thyrotoxicosis</li>
          <li>The ultimate thyroid failure seen in some patients is thought to result from the presence of blocking antibodies against the TSH receptor, and from tissue destruction by cytotoxic antibodies and cell-mediated immunity</li>
        </ul>

        <p><strong>Genetic factors:</strong></p>
        <ul>
          <li>In Caucasians there is an association of Graves' disease with HLA-B8, DR3 and DR2</li>
          <li>Association with inability to secrete the water-soluble glycoprotein form of the ABO blood group antigens</li>
          <li>50% of monozygotic twins are concordant for thyrotoxicosis, as opposed to 5% of dizygotic twins</li>
        </ul>

        <p><strong>Triggers:</strong></p>
        <ul>
          <li>Infection with viruses or bacteria (unproven)</li>
          <li>Iodine supplementation (in regions of iodine deficiency, but only in those with pre-existing subclinical Graves' disease)</li>
          <li>Smoking is weakly associated with Graves' thyrotoxicosis, but strongly linked with the development of ophthalmopathy</li>
        </ul>

        <p><strong>Other Causes of Hyperthyroidism:</strong></p>
        <ul>
          <li><strong>Multinodular goitre</strong></li>
          <li><strong>Autonomously functioning solitary thyroid nodule</strong></li>
          <li><strong>Thyroiditis:</strong>
            <ul>
              <li>Subacute (de Quervain's)</li>
              <li>Post-partum</li>
            </ul>
          </li>
          <li><strong>Iodine induced:</strong>
            <ul>
              <li>Drugs (e.g. amiodarone)</li>
              <li>Radiographic contrast media</li>
              <li>Iodine prophylaxis programme</li>
            </ul>
          </li>
          <li><strong>Extrathyroidal:</strong>
            <ul>
              <li>Factitious hyperthyroidism</li>
              <li>Struma ovarii (Ovarian teratoma containing thyroid tissue)</li>
            </ul>
          </li>
          <li><strong>TSH induced:</strong>
            <ul>
              <li>TSH-secreting pituitary adenoma</li>
              <li>Choriocarcinoma and hydatidiform mole (HCG is thyroid stimulating)</li>
            </ul>
          </li>
          <li><strong>Follicular carcinoma ± metastases</strong></li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>5. In considering further investigation of Shelley, outline the different types of thyroid autoantibodies and their prevalence in different thyroid conditions.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <table>
          <tr>
            <th></th>
            <th colspan="3">Antibodies to:</th>
          </tr>
          <tr>
            <th></th>
            <th>Thyroid peroxidase<sup>1</sup></th>
            <th>Thyroglobulin</th>
            <th>TSH receptor<sup>2</sup></th>
          </tr>
          <tr>
            <td>Normal population</td>
            <td>8-27%</td>
            <td>5-20%</td>
            <td>0%</td>
          </tr>
          <tr>
            <td><strong>Graves' disease</strong></td>
            <td>50-80%</td>
            <td>50-70%</td>
            <td><strong>80-95%</strong></td>
          </tr>
          <tr>
            <td><strong>Autoimmune hypothyroidism</strong></td>
            <td><strong>90-100%</strong></td>
            <td>80-90%</td>
            <td>10-20%</td>
          </tr>
          <tr>
            <td>Multinodular goitre</td>
            <td>30-40%</td>
            <td>30-40%</td>
            <td>0%</td>
          </tr>
          <tr>
            <td>Transient thyroiditis</td>
            <td>30-40%</td>
            <td>30-40%</td>
            <td>0%</td>
          </tr>
        </table>
        <p><sup>1</sup>Thyroid peroxidase antibodies are the principal component of what was previously measured as thyroid 'microsomal' antibodies.</p>
        <p><sup>2</sup>TSH receptor antibodies (TRAb) can be agonists (causing Graves' thyrotoxicosis) or antagonists (causing hypothyroidism).</p>
      </div>
    </div>

    <div class="question">
      <strong>6. Briefly describe the use of radio-iodine uptake tests in the assessment of hyperthyroidism.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Radio-iodine uptake tests measure the proportion of isotope which is trapped in the whole gland, but have been largely superseded by <sup>99m</sup>technetium scintigraphy scans which also measure trapping, are quicker to perform with a lower dose of radioactivity, and provide a higher resolution image.</p>

        <p><strong>Scintigraphy findings in different conditions:</strong></p>
        <ul>
          <li><strong>Graves' disease:</strong> Diffuse uptake of isotope throughout the gland</li>
          <li><strong>Multinodular goitre (MNG):</strong> Relatively low, patchy uptake within the nodules; such an appearance is not always associated with a palpable thyroid</li>
          <li><strong>Toxic adenoma:</strong> Lack of uptake of isotope by normal dormant gland due to suppression of serum TSH</li>
          <li><strong>Low-uptake thyrotoxicosis</strong> (viral, post-partum or iodine-induced thyroiditis): Negligible isotope detected in the region of the thyroid, although uptake is apparent in nearby salivary glands</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>7. Shelley asks about treatment of the condition; Summarise the mechanism of action of antithyroid drugs and the main side effects of each type of medication.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Definitive treatment of thyrotoxicosis depends on the underlying cause, and may include antithyroid drugs, radioactive iodine or surgery.</p>

        <p><strong>Beta-blockers (all patients):</strong></p>
        <ul>
          <li>A non-selective β-adrenoceptor antagonist (β-blocker) will alleviate but not abolish symptoms within 24-48 hours</li>
          <li>Cannot be recommended for long-term treatment</li>
          <li>Extremely useful in the short term, e.g. for patients awaiting hospital consultation or following <sup>131</sup>I therapy</li>
        </ul>

        <table>
          <tr>
            <th>Treatment</th>
            <th>Common indications</th>
            <th>Contraindications</th>
            <th>Disadvantages/complications</th>
          </tr>
          <tr>
            <td><strong>Antithyroid drugs</strong><br>(e.g. carbimazole, propylthiouracil)</td>
            <td>First episode in patients < 40 yrs<br>Breastfeeding (propylthiouracil suitable)</td>
            <td></td>
            <td>>50% relapse rate usually within 2 years of stopping drug<br>Hypersensitivity rash 2%<br><strong>Agranulocytosis 0.2%</strong></td>
          </tr>
          <tr>
            <td><strong>Subtotal thyroidectomy</strong></td>
            <td>Large goitre<br>Poor drug compliance, especially in young patients<br>Recurrent thyrotoxicosis after course of antithyroid drugs in young patients</td>
            <td>Previous thyroid surgery<br>Dependence upon voice, e.g. opera singer</td>
            <td>Hypothyroidism (25%)<br>Transient hypocalcaemia (10%)<br>Permanent hypoparathyroidism (1%)<br>Recurrent laryngeal nerve palsy (1%)</td>
          </tr>
          <tr>
            <td><strong>Radio-iodine</strong></td>
            <td>Patients > 40 yrs<br>Recurrence following surgery irrespective of age<br>Other serious comorbidity</td>
            <td>Pregnancy or planned pregnancy within 6 months of treatment<br>Active Graves' ophthalmopathy</td>
            <td>Hypothyroidism, approx. 40% in first year, 80% after 15 years<br>Most likely treatment to result in exacerbation of ophthalmopathy</td>
          </tr>
        </table>
      </div>
    </div>

    <div class="question">
      <strong>8. Radioactive iodine or surgery are other management options for thyroid disease. a) Briefly outline the mechanism of action of radioactive iodine. b) Summarise the indications for and possible complications of surgery.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>a) Mechanism of action of radioactive iodine:</strong></p>
        <ul>
          <li>Radioactive iodine, <sup>131</sup>I, is administered orally as a single dose and is trapped and organified in the thyroid</li>
          <li>Although it will decay within the thyroid in a few weeks, the effects of its radiation are long-lasting, with cumulative effects on follicular cell survival and replication</li>
          <li>The variable radio-iodine uptake and radiosensitivity of the gland means that the choice of dose is empirical</li>
          <li>Effective in 75% of patients within 4-12 weeks</li>
          <li>During the lag period, symptoms can be controlled by a β-blocker or, in more severe cases, by carbimazole</li>
          <li>However, carbimazole reduces the efficacy of <sup>131</sup>I therapy because it prevents organification of <sup>131</sup>I in the gland, and so should be avoided until 48 hours after radio-iodine administration</li>
          <li>If thyrotoxicosis persists after 12-24 weeks, a further dose of <sup>131</sup>I should be employed</li>
          <li>The disadvantage of <sup>131</sup>I treatment is that the majority of patients eventually develop hypothyroidism and long-term follow-up is, therefore, necessary</li>
        </ul>

        <p><strong>b) Surgery (Subtotal thyroidectomy):</strong></p>
        <p><em>Indications:</em></p>
        <ul>
          <li>Large goitre</li>
          <li>Poor drug compliance, especially in young patients</li>
          <li>Recurrent thyrotoxicosis after course of antithyroid drugs in young patients</li>
        </ul>

        <p><em>Preparation:</em></p>
        <ul>
          <li>Patients must be rendered euthyroid with antithyroid drugs before operation</li>
          <li>Potassium iodide is often added before surgery to inhibit thyroid hormone release and reduce the size and vascularity of the gland, making surgery technically easier</li>
        </ul>

        <p><em>Complications:</em></p>
        <ul>
          <li>Hypothyroidism (25%)</li>
          <li>Transient hypocalcaemia (10%)</li>
          <li>Permanent hypoparathyroidism (1%)</li>
          <li>Recurrent laryngeal nerve palsy (1%)</li>
          <li>Note: It is not only vocal cord palsy due to recurrent laryngeal nerve damage which alters the voice; the superior laryngeal nerves are frequently transected and result in minor changes in voice quality</li>
        </ul>

        <p><em>Outcome:</em></p>
        <ul>
          <li>One year after surgery, 80% of patients are euthyroid, 15% are permanently hypothyroid and 5% remain thyrotoxic</li>
          <li>Thyroid failure within 6 months of operation may be temporary</li>
          <li>Long-term follow-up is necessary, as the late development of hypothyroidism and recurrence of thyrotoxicosis are well recognised</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>9. Briefly outline what is meant by the term 'thyroid storm' and explain why it is considered an emergency situation.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Thyrotoxic crisis ('thyroid storm'):</strong></p>
        <p>This is a rare, life-threatening increase in the severity of the clinical features of thyrotoxicosis.</p>

        <p><strong>The most prominent signs are:</strong></p>
        <ul>
          <li>Fever</li>
          <li>Agitation</li>
          <li>Confusion</li>
          <li>Tachycardia or AF (and possibly cardiac failure in the older patient)</li>
        </ul>

        <p><strong>Why it is an emergency:</strong></p>
        <ul>
          <li>It is a medical emergency</li>
          <li>Despite early recognition and treatment, the mortality rate is 10%</li>
        </ul>

        <p><strong>Precipitating factors:</strong></p>
        <ul>
          <li>Most commonly precipitated by infection in a patient with previously unrecognised or inadequately treated thyrotoxicosis</li>
          <li>May develop shortly after subtotal thyroidectomy in an ill-prepared patient</li>
          <li>May occur within a few days of <sup>131</sup>I therapy when acute irradiation damage may lead to a transient rise in serum thyroid hormone levels</li>
        </ul>
      </div>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/user-analytics.js"></script>
  <script src="../js/analytics-integration.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        
    }
      
    }
    
    }
// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      
    }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      
    }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          
    }
        }, 100);
      
    }
    });
    
    }
  </script>

  <script src="../js/case-page-tracker.js"></script>
</body>
</html>